Glenmark Pharmaceuticals has informed about submission of media release titled ‘Glenmark Pharmaceuticals receives ANDA approval for Ranolazine Extended?Release Tablets, 500 mg and 1,000 mg’ which is self explanatory.
The above information is a part of company’s filings submitted to BSE.